3,851 reports of this reaction
7.6% of all IXEKIZUMAB reports
#1 most reported adverse reaction
INJECTION SITE PAIN is the #1 most commonly reported adverse reaction for IXEKIZUMAB, manufactured by Eli Lilly and Company. There are 3,851 FDA adverse event reports linking IXEKIZUMAB to INJECTION SITE PAIN. This represents approximately 7.6% of all 50,855 adverse event reports for this drug.
Patients taking IXEKIZUMAB who experience injection site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE PAIN is moderately reported among IXEKIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to injection site pain, the following adverse reactions have been reported for IXEKIZUMAB:
The following drugs have also been linked to injection site pain in FDA adverse event reports:
INJECTION SITE PAIN has been reported as an adverse event in 3,851 FDA reports for IXEKIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE PAIN accounts for approximately 7.6% of all adverse event reports for IXEKIZUMAB, making it one of the most commonly reported side effect.
If you experience injection site pain while taking IXEKIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.